TD Cowen named Royalty Pharma as its top pharma pick for 2027, citing the company's position as the leading purchaser of biopharma royalties and its ability to benefit from industry tailwinds while carrying lower risks than traditional pharmaceutical companies.
The firm projects compound revenue and earnings growth of 7% from 2025 to 2032, roughly in line with industry averages. Royalty Pharma's business model allows it to participate in biopharma upside while reducing exposure to clinical, commercial, and patent risks.
TD Cowen acknowledged investor concerns including an ongoing arbitration with Vertex over the Alyftrek royalty, future deal visibility, valuation comparability challenges, competition risk, and tax exposure. The firm expects the Vertex arbitration to resolve by mid-2027, potentially removing uncertainty. TD Cowen's model shows robust topline growth even assuming an unfavorable arbitration outcome.
Royalty Pharma trades at 11.8 times TD Cowen's 2027 earnings estimate, a 23% discount to the pharma industry's 15.4 times multiple. TD Cowen raised its price target to $80, or 13.8 times its 2027 earnings estimate, arguing the company merits a premium valuation given lower downside risk and potential for upward earnings revisions.